$13.05
2.35% today
NYSE, Apr 01, 06:19 pm CET
ISIN
US29082K1051
Symbol
EMBC

Embecta Stock price

$12.75
-0.75 5.56% 1M
-1.35 9.57% 6M
-7.90 38.26% YTD
-0.36 2.75% 1Y
-20.58 61.75% 3Y
-34.25 72.87% 5Y
-34.25 72.87% 10Y
NYSE, Closing price Mon, Mar 31 2025
+0.47 3.83%
ISIN
US29082K1051
Symbol
EMBC
Sector

Key metrics

Market capitalization $741.21m
Enterprise Value $2.12b
P/E (TTM) P/E ratio 12.68
EV/FCF (TTM) EV/FCF 73.26
EV/Sales (TTM) EV/Sales 1.91
P/S ratio (TTM) P/S ratio 0.67
P/B ratio (TTM) P/B ratio negative
Dividend yield 4.71%
Last dividend (FY24) $0.60
Revenue growth (TTM) Revenue growth -1.31%
Revenue (TTM) Revenue $1.11b
EBIT (operating result TTM) EBIT $182.10m
Free Cash Flow (TTM) Free Cash Flow $28.90m
Cash position $216.70m
EPS (TTM) EPS $1.01
P/E forward 7.99
P/S forward 0.68
EV/Sales forward 1.95
Short interest 4.46%
Show more

Is Embecta a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,804 stocks worldwide.

Embecta Stock Analysis

Unlock Scores for Free

Analyst Opinions

4 Analysts have issued a Embecta forecast:

1x Buy
25%
2x Hold
50%
1x Sell
25%

Analyst Opinions

4 Analysts have issued a Embecta forecast:

Buy
25%
Hold
50%
Sell
25%

Financial data from Embecta

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
1,108 1,108
1% 1%
100%
- Direct Costs 410 410
9% 9%
37%
698 698
7% 7%
63%
- Selling and Administrative Expenses 392 392
11% 11%
35%
- Research and Development Expense 79 79
11% 11%
7%
227 227
3% 3%
21%
- Depreciation and Amortization 45 45
31% 31%
4%
EBIT (Operating Income) EBIT 182 182
2% 2%
16%
Net Profit 58 58
5% 5%
5%

In millions USD.

Don't miss a Thing! We will send you all news about Embecta directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Embecta Stock News

Neutral
GlobeNewsWire
about 5 hours ago
PARSIPPANY, N.J., April 01, 2025 (GLOBE NEWSWIRE) -- Embecta Corp. ("embecta") (Nasdaq: EMBC), a global diabetes care company with a 100-year legacy in insulin delivery, today announced a new landmark publication in the Mayo Clinic Proceedings.
Neutral
Seeking Alpha
about one month ago
Embecta faces headwinds from new insulin delivery technologies and GLP-1 drugs, but its valuation is compelling with a ~44% free cash flow yield on guided free cashflow. EMBC's end market is expected to witness a headwind from increased use of pump patches in comparison to traditional insulin delivery routes. Moreover, increased GLP-1 use to treat diabetes would lead to further less frequent us...
Neutral
GlobeNewsWire
about one month ago
PARSIPPANY, N.J., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Embecta Corp. (embecta) (Nasdaq: EMBC) today announced that Jake Elguicze, embecta's Chief Financial Officer, will present at the J.P. Morgan Global Leveraged Finance Conference in Miami on Tuesday, February 25, 2025 at 3:00 p.m. ET.
More Embecta News

Company Profile

Embecta Corp. engages in the provision of medical devices used in the treatment of diabetes. Its products include pen needles, syringes, and safety devices complemented by a digital application. The company was founded in 1924 and is headquartered in Parsippany, NJ.

Head office United States
CEO Devdatt Kurdikar
Employees 2,100
Founded 1924
Website www.embecta.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today